Cyclin D1 Binds the Androgen Receptor and Regulates Hormone-Dependent Signaling in a p300/CBP-Associated Factor (P/CAF)-Dependent Manner
Anne T. Reutens1,
Maofu Fu1,
Chenguang Wang,
Chris Albanese,
Michael J. McPhaul,
Zijie Sun,
Steven P. Balk,
Olli A. Jänne,
Jorma J. Palvimo and
Richard G. Pestell
The Albert Einstein Comprehensive Cancer Center (A.T.R., M.F.,
C.W., C.A., R.G.P.) Division of Hormone-Dependent Tumor Biology
Department of Developmental and Molecular Biology Albert Einstein
College of Medicine Bronx, New York 10461
Department of
Internal Medicine (M.J.M.) University of Texas Southwestern Medical
Center, Dallas Dallas, Texas 75235-8857
Department of
Surgery and Genetics (Z.S.) Stanford University School of
Medicine Stanford, California 943054
Hematology-Oncology
Division (S.P.B.) Department of Medicine Beth Israel
Hospital Boston, Massachusetts 02215
Department of
Physiology (O.A.J., J.J.P.) Institute of Biomedicine and Department
of Clinical Chemistry University of Helsinki FIN-00014
Helsinki, Finland
 |
ABSTRACT
|
---|
The androgen receptor (AR) is a ligand-regulated
member of the nuclear receptor superfamily. The cyclin D1
gene product, which encodes the regulatory subunit of holoenzymes that
phosphorylate the retinoblastoma protein (pRB), promotes cellular
proliferation and inhibits cellular differentiation in several
different cell types. Herein the cyclin D1 gene product
inhibited ligand-induced AR- enhancer function through a
pRB-independent mechanism requiring the cyclin D1 carboxyl terminus.
The histone acetyltransferase activity of P/CAF (p300/CBP
associated factor) rescued cyclin D1-mediated AR
trans-repression. Cyclin D1 and the AR both bound to
similar domains of P/CAF, and cyclin D1 displaced binding of the AR to
P/CAF in vitro. These studies suggest cyclin D1 binding to
the AR may repress ligand-dependent AR activity by directly competing
for P/CAF binding.
 |
INTRODUCTION
|
---|
The androgen receptor (AR) is a member of a nuclear receptor
superfamily that regulates ligand-dependent gene transcription through
binding DNA and interacting with other transcription factors (1, 2). In
response to the ligand, nuclear receptors coordinate diverse
physiological roles in the regulation of metabolism and development.
Androgens induce differentiation of male reproductive organs (3).
Inherited mutations of the AR result in defective induction of male
secondary sexual characteristics (3), and somatic mutations of the AR
have been linked to therapy resistance in patients with prostate
cancers (4). The AR contains distinct functional domains (termed AF),
which are conserved with other members of the "classical" receptor
subclass, comprising receptors for estrogens (ER), progestins (PR),
glucocorticoids (GR), and mineralocorticoids (MR). Ligand-bound
activated nuclear receptors direct the assembly and stabilization of a
preinitiation complex at a target gene promoter through forming direct
associations with the basal transcription apparatus and with
hormone-dependent cofactors (5). In vitro analysis
identified interactions between nuclear receptors and components of the
basal transcription apparatus, including TATA-binding protein
(TBP) and TAFII30 (6). These interactions are
necessary but not sufficient for efficient transactivation, which
requires additional coactivator proteins (7).
Coactivator proteins for the steroid receptors can be classified into
structurally related groups and include the cointegrators
[CREB-binding protein (CBP) and the related functional homolog p300
(8)], the steroid receptor coactivators (SRC-1), (also referred to as
p160/NCoA-1 or ERAP-160) and related family members (9), and the
steroid receptor RNA activator (SRA) (10). SRC family proteins and
several other nuclear receptor coregulators contain a conserved
leucine-rich domain (LXXLL) and an adjacent basic region that together
serve as a nuclear receptor interaction motif (9, 11). Coactivator
recruitment to a nuclear receptor involves sequential docking through
the basic region to charged residues on the receptor, and then docking
of the LXXLL motif (11). The cointegrator proteins, p300/CBP and the
SRC family, share the capacity to acetylate histones, which often
correlates in part with their transcriptional coactivator function
(12). The enhancement of transcriptional activity by p300/CBP requires
a bridging function to associate transcription factors with the basal
transcription apparatus (13), and both intrinsic and associated histone
acetyltransferase (HAT) activity, which are separable functions.
Acetylation facilitates binding of transcription factors to
specific target DNA sequences by destabilizing nucleosomes bound to the
promoter region of a target gene (14, 15, 16, 17). The mammalian P/CAF
(p300/CBP-associated factor), which contributes the
p300/CBP-associated HAT activity, is homologous to the yeast HAT
and transcriptional adaptor GCN5 (18). P/CAF inhibited cell cycle
progression (18) and promoted myocyte differentiation (19), suggesting
P/CAF may also regulate components of the cell cycle.
The eukaryotic cell cycle contains critical genetically conserved
components that subserve distinct functions (20, 21). The
G1 cyclins are of two classes: the D type cyclins
(D1, D2, and D3) and cyclin E. The D type cyclins share structurally
conserved motifs that interact with cyclin-dependent kinases 4 and
6 (cdk4/cdk6) and pRB (retinoblastoma protein). The cyclin
D1 gene has been implicated in a subset of human tumors including
breast and prostate cancer, and overexpression of cyclin D1 has been
linked to tumor therapy resistance. Cyclin D1 collaborates with other
oncogenes in cellular transformation (22), and cyclin D1 abundance is
induced by oncogenic protein including mutants of Ras (23), Rac1 (24, 25), pp60src (26), STAT3 (signal transducer and
activator of transcription 3) (27), and ß-catenin/APC mutants (28).
The proliferative and oncogenic properties of cyclin D1 may relate to
its function as the regulatory subunit of the holoenzyme that
phosphorylates and inactivates the tumor suppressor pRB (20, 21).
However, cyclin D1 conveys holoenzyme-independent function, inhibiting
myocyte differentiation (29) through partially pRB-independent means
(30) and binding the estrogen receptor (ER) to induce activity in a
ligand-independent manner (31, 32, 33).
In the current studies, we show that cyclin D1 selectively inhibits
ligand-dependent AR function in prostate cancer cells through a
pRB-independent mechanism. The ligand dependency of this interaction
contrasts fundamentally with the previously described
ligand-independent interaction of cyclin D1 with the ER
. Cyclin D1
inhibition of ligand-dependent AR function required a carboxyl terminal
acidic-rich region that is structurally divergent from cyclin D2 and
D3. Cyclin D1 binding to the AR also required the cyclin D1 acidic-rich
carboxyl terminus. The correlation between cyclin D1 binding to the AR
in vitro and the repression of hormone-dependent AR activity
in vivo suggests either a physical interaction between
cyclin D1 and the AR may form a repressor complex or that the AR and
cyclin D1 may compete for a common coactivator. p300 antagonized the
cyclin D1 repressor function, which occurs independently of p300s
intrinsic HAT activity, and required the associated HAT activity of
P/CAF. Cyclin D1 associated directly with P/CAF. Cyclin D1 and
the AR bound to the same domains of P/CAF. Cyclin D1 repression of
liganded AR activity may involve competition with the AR for binding to
limiting cellular P/CAF.
 |
RESULTS
|
---|
Cyclin D1 Inhibits Ligand-Dependent AR Transactivation
To examine cyclin D1 regulation of an androgen-
responsive reporter gene, the AR-deficient prostate cancer cell
line DU145 was transfected with the wild-type human AR and the
androgen-responsive mouse mammary tumor virus (MMTV)-LUC
reporter (Fig. 1A
). Dihydrotestosterone
(DHT) induced reporter activity 5-fold, and coexpression of cyclin D1
inhibited this activity by 60% (Fig. 1A
). Cyclin D1-mediated
repression of DHT-induced MMTV-LUC reporter activity was observed in
DU145 cells at several different concentrations of DHT (0.1
nM to 100 nM) (Fig. 1B
). To examine further the
promoter specificity of cyclin D1-mediated repression, several
different control reporter constructions were examined in DU145 cells
in the presence of the AR and DHT. The activity of the viral promoters
[cytomegalovirus (CMV)-LUC, rous sarcoma virus (RSV)-LUC] and the
luciferase reporter vectors were not regulated by cyclin D1 (Fig. 1C
).
Neither cyclin D2 nor cyclin D3 inhibited AR activity (Fig. 1D
).

View larger version (26K):
[in this window]
[in a new window]
|
Figure 1. Cyclin D1 Inhibits Ligand-Dependent AR Activity
A, The MMTV luciferase reporter (2.4 µg) was transfected into DU145
cells with the expression vector encoding the human AR either in the
presence or absence of cyclin D1 (pCMV-cyclin D1). Comparison was made
with the effect of the expression of equal amounts of empty expression
vector cassette (pRC CMV). DHT was added as indicated. The results are
shown as mean ± SEM throughout. B, Cyclin D1-mediated
repression of DHT-induced MMTV-LUC reporter activity was observed in
DU145 cells and occurred at several different concentrations of DHT
(0.1 nM to 100 nM). C, The effect of cyclin D1
on activity of several other reporter plasmids was determined in DU145
cells. Luciferase activity of the promoters, other than MMTV, was not
affected by cyclin D1 in the presence of ligand and AR. D, The effect
of cyclins D2 and D3 on MMTV-LUC activity in DU145 cells treated with
DHT (10-7 M). E, The effect of cyclin D1 on
the activity of the MMTV-LUC reporter and several other reporter genes
(F) was assessed in the PC3 cell line in the presence of the AR
expression plasmid and treated with DHT (10-7
M).
|
|
To determine whether cyclin D1-mediated repression of ligand-induced
AR-dependent reporter activity was observed in other prostate cancer
cell lines, PC3 cells were transfected with the MMTV-LUC reporter.
DHT-induced the MMTV-LUC reporter 7-fold, and the ligand-induced, but
not the basal, activity of the reporter was inhibited by cyclin D1
(Fig. 1E
). Additional reporter genes were examined to determine the
specificity of cyclin D1-mediated repression of DHT- induced AR
activity. Reporter constructions were used encoding immediate early
gene promoters (c-jun LUC, junB LUC), synthetic
response elements (SRE LUC, E2F LUC), and the promoters of cell cycle
control genes (cyclin D1 LUC, cyclin E LUC,
p21Cip1/WAF1 LUC). In contrast with the MMTV-LUC
reporter, cyclin D1 failed to repress the additional promoter reporter
constructions (Fig. 1F
). Repression of AR activity was also observed in
293T cell lines (data not shown). These studies suggest that cyclin D1
repression of DHT-induced AR transcriptional activity is promoter
specific.
A Structurally Divergent Acid-Rich Motif in the Carboxyl Terminus
of Cyclin D1 Is Required for Repression of AR Activity
To determine the domains of cyclin D1 involved in repression
of AR activity, expression plasmids encoding mutant cyclin D1 were
constructed and characterized in cultured mammalian cells. The carboxyl
terminus of cyclin D1 diverges structurally from cyclin D2
and D3 (Fig. 2A
) due
to the presence of an acid-rich region (residues 272280). The
expression of the cyclin D1 mutants was assessed in cultured cells by
Western blotting. Sequential deletion of the extreme carboxyl terminus
did not reduce cyclin D1 protein abundance expressed in cultured cells
(Fig. 2B). The abundance of the cyclin D1 mutants was also similar
to wild type cyclin D1 in the presence of DHT (Fig. 2B
, lower
panel). Abundance of the carboxyl-terminal deletion mutant (CD1
C241) was increased 2-fold in abundance compared with wild type. To
identify the domains of cyclin D1 required for repression of AR
activity, cotransfection experiments were conducted with either the
wild-type or the mutant cyclin D1 expression vectors. Deletion of the
C-terminal 21 amino acids (CD1
C274) reduced AR repression by 50%
(Fig. 2C
). Deletion of an additional three additional residues (CD1
C271) or point mutation of the cyclin D1 carboxyl-terminal LLXXXL
motif (leucines 254/255) abolished AR repression (Fig. 2C
). The
repression of DHT-induced AR activity was increased 25% by the
pRB-binding defective mutant (GH) (Fig. 2C
). The cdk-binding defective
cyclin D1 mutant (KE) was partially defective in AR repression (Fig. 2C
). Therefore, the carboxyl terminus of cyclin D1 is required for full
repression of AR activity. The finding that the pRB-binding domain of
cyclin D1 is not required for repression is consistent with the
observation that cyclin D1 inhibits DHT-induced AR activity in DU145
cells that are pRB deficient.

View larger version (22K):
[in this window]
[in a new window]
|
Figure 2. The Cyclin D1 Carboxyl Terminus Is Required for
Inhibition of Liganded AR Activity
A, Alignment of carboxyl termini amino acid sequence for cyclin D1
(D1), cyclin D2, and cyclin D3 and a schematic representation of the
cyclin D1 mutant expression plasmids: cdk-binding defective (CD1 KE),
pRB-binding defective (CD1 GH), deleted of the carboxyl terminus, or
point mutated within the cyclin D1 LLXXXL motif (36 ). B, The cyclin D1
expression plasmids were transfected into cyclin D1-deficient 293T
cells. After 24 h the cells were harvested and Western blotting
was performed using the cyclin D1 antibody as described in
Materials and Methods. The abundance of the cyclin D1
mutant proteins was assessed by Western blotting either without
(upper panel) or with DHT (10-6
M) for 24 h (lower panel). C, The
inhibition of DHT (10-7 M)-induced MMTV-LUC
reporter activity by the wild-type or mutant cyclin D1 expression
plasmids is shown with the repression by wild-type cyclin D1, shown as
100%, in DU145 cells. The data are shown as mean ±
SEM for n = 9.
|
|
Cyclin D1 Binds the AR Hinge Region
To determine whether AR regulation by cyclin D1 may involve a
direct protein-protein interaction, we examined cyclin D1 binding
to the AR using either immunoprecipitation (IP) followed by
Western blotting (Fig. 3A
) or
glutathione-S-transferase (GST) pull-down assay. 293T cells
were used as they have high transfection efficiency and are AR
deficient. Cells were transfected with expression vectors encoding
either wild-type or mutant AR and cyclin D1 (Fig. 3A
) and treated with
DHT or vehicle for 24 h, after which IP was performed on equal
amounts of protein extracts using a cyclin D1-specific antibody
(DCS-11). Western blotting was then performed for the AR and cyclin D1
using specific antibodies. Wild-type AR immunoreactivity was observed
in the cyclin D1 IP (Fig. 3A
, lanes 1 and 2) but not in the IP from
cells transfected with the empty expression vector cassette (Fig. 3A
, lanes 9 and 10) or from IPs performed with control IgG (data not
shown). AR immunoreactivity was observed in the cyclin D1 IP from cells
transfected with the AR mutants with deleted amino acids 8093,
96483, and 707902 (Fig. 3A
, lanes 38). The C-terminal mutant AR
1707 bound cyclin D1 with no alteration in the amount of binding in
response to DHT treatment, consistent with the known deletion of most
of the ligand-binding domain in AR 1707. These results suggest that
the AR between residues 483 and 707 can bind cyclin D1.

View larger version (35K):
[in this window]
[in a new window]
|
Figure 3. Cyclin D1 Binds Wild-Type AR in Cultured Cells and
in Vitro
A, Schematic representation of the AR mutant expression vectors
indicating the DNA binding domain (DBD) and the carboxyl terminal
ligand-binding domain (LBD). Wild-type or mutant AR and the wild-type
cyclin D1 expression vectors were transfected into 293T cells. IP was
performed with the cyclin D1 antibody, and precipitates were analyzed
by Western blotting with either the AR antibody (above)
or the cyclin D1 antibody (lower panel).
B, Schematic representation of GST-AR fusion proteins. GST-AR fusion
products were incubated with equal amounts of in vitro
expressed cyclin D1. GST pull downs were performed using the in
vitro translated product from the full-length human cyclin D1
cDNA and equal amounts of GST-AR protein, and the products were
separated by SDS-PAGE. The relative amount of cyclin D1 bound to the
GST-AR fragment was determined by densitometry, and percent binding is
shown adjacent to the GST-AR fusion proteins. Data are the mean of
three separate experiments. An example of GST-AR pull-down interaction
with in vitro translated cyclin D1. The
[35S]-labeled cyclin D1 band is indicated. The GST-AR
region AR-633668 is sufficient for specific binding to cyclin D1. C,
GST pull downs were performed with GST-AR/633668 and in
vitro expressed cyclin D2 or cyclin D3. Equal amounts of each
of the D type cyclins were used as input. The binding of GST-AR to
either cyclin D2 or cyclin D3 was similar to GST alone.
|
|
The binding of GST-AR fusion proteins to in vitro translated
cyclin D1 was next assessed (Fig. 3B
). The abundance of cyclin D1 in
the pull down was determined by densitometry of the
[35S]-labeled cyclin D1 product. The binding
affinity for each AR fragment was expressed relative to the nonspecific
binding of GST. The GST-AR fragment AR/505676 bound with high
affinity to cyclin D1 (Fig. 3B
). The GST-AR/633668 bound cyclin D1,
but neither the GST-AR/505559 nor GST-AR/552635 bound to cyclin D1,
indicating that AR residues 633668 are sufficient for cyclin D1
binding.
Experiments were conducted to determine whether cyclin D2 or cyclin D3
was capable of binding to the AR hinge region. GST pull-down analyses
were performed using equal amounts of GST-AR fusion protein and equal
amounts of in vitro translated D type cyclin (Fig. 3C
). In
contrast with cyclin D1, neither cyclin D2 nor cyclin D3 bound to
GST-AR when compared with the nonspecific binding of GST.
The Cyclin D1 Acid-Rich Carboxyl Terminus Binds the AR
To identify the region of cyclin D1 required for binding to the
AR, GST pull-down experiments were performed in which in
vitro translated cyclin D1 mutants were incubated with the GST-AR
fragment AR/505676. Comparison was made to the binding of wild- type
cyclin D1 set as 100%. The mean binding data of three separate
experiments are shown in Fig. 4
. Mutation
of the cdk-binding domain did not reduce AR binding. Mutation of
leucines 254 and 255 in cyclin D1 diminished AR binding by only 20%,
and deletion of 21 amino acids from the cyclin D1 C terminus decreased
binding by 64%. The cyclin D1 mutant
C267 and other deletions of
the C terminus gave negligible binding to the AR.

View larger version (21K):
[in this window]
[in a new window]
|
Figure 4. The Carboxyl Terminus of Cyclin D1 Is Required for
AR Binding
[35S]-labeled cyclin D1 proteins, shown schematically,
were incubated with equal amounts of GST-AR fusion protein (AR
633668), and GST pull-down experiments were conducted. The results of
a representative pull-down experiment are shown. The relative amount of
cyclin D1 bound to the GST-AR fragment was determined by densitometry.
The percent binding is shown adjacent to the cyclin D1 mutant and
graphically for the mean of at least two separate experiments.
|
|
The P/CAF Histone Acetylase Domain Relieves Cyclin
D1-Mediated AR Repression
We examined the mechanisms by which cyclin D1
repressed AR activity, hypothesizing that cyclin D1 may either bind the
AR to form a repressor complex or interfere with coactivators
regulating AR activity. We investigated the role of p300 in cyclin
D1-mediated AR repression (Fig. 5A
). In
previous studies, the abundance of the mutant p300 proteins was shown
to be similar to the wild type when transfected into mammalian cells.
Overexpression of p300 decreased cyclin D1 repression of MMTV-LUC
activity from 75% repression to 25% (Fig. 5A
). To examine candidate
functional domains of p300 required for antagonism of cyclin
D1-mediated AR repression, mutants of the p300 bromo-domain
(
10321138), the HAT domain (
14191721), and the CH3 region
(
17371809) were assessed (Fig. 5A
). The p300 CH3 region
17371809 mutant failed to rescue cyclin D1-mediated AR
transcriptional repression (Fig. 5A
). Deletion of the p300 HAT domain
induced activity further than wild-type p300, suggesting the p300 HAT
domain was not required for rescue.

View larger version (31K):
[in this window]
[in a new window]
|
Figure 5. Cyclin D1-Mediated AR Repression Is Relieved by
either p300 or P/CAF
A, The MMTV-LUC reporter was transfected into DU145 cells and
cotransfected with the human AR, cyclin D1, and p300 as indicated.
Shown on the top is the schematic representation of the
p300 expression vectors. The bromo, HAT, and CH3-binding domains are
shown. The data are shown as the mean ± SEM. DHT
treatment (10-7 M) was for 24 h. The
repression of DHT-dependent induction of MMTV-LUC activity by cyclin D1
is shown. B, Schematic representation of the P/CAF expression vector
showing the HAT domain, and the regions homologous to the Ada2 and
bromo domains. Western blotting is shown of extracts from DU145 cells
transfected with the Flag-tagged P/CAF expression vectors using the
anti-Flag (M2) antibody. The membrane was probed with the GDI antibody
as a protein loading control. The P/CAF wild-type or mutant expression
vectors were cotransfected with the MMTV-LUC reporter in the presence
of AR. DHT treatment was for 24 h. The repression of DHT-dependent
induction of MMTV-LUC activity by cyclin D1 is shown as the mean
± SEM of five separate transfections. The
carboxyl-terminal region of the P/CAF HAT domain is required for rescue
of cyclin D1-mediated AR repression.
|
|
The CH3 region of p300 is known to interact with P/CAF and thereby
contribute to the HAT activity of p300/CBP. We examined the possibility
that P/CAF was the p300-associated factor required for relief of cyclin
D1-mediated AR repression. P/CAF has intrinsic HAT activity (18)
located within a domain adjacent to the Ada2 homology region (Fig. 5B
)
(34). The abundance of wild-type and mutant P/CAF expressed in cultured
cells was assessed by Western blotting. DU145 cells were transfected
with the Flag-tagged P/CAF expression plasmids, and Western blotting
was performed with the anti-Flag antibody. The P/CAF mutant protein
P/CAF
609624 was expressed equally to the wild- type protein (Fig. 5B
). Cyclin D1-mediated AR repression was antagonized by P/CAF
overexpression (Fig. 5B
). The P/CAF HAT domain deletion mutant (P/CAF
609624), however, failed to rescue and further inhibited
DHT-induced AR activity (Fig. 5B
). These studies indicate that P/CAF
HAT activity is required for the reversal of cyclin D1-mediated AR
repression.
Cyclin D1 and P/CAF Binding in Cultured Cells and in
Vitro
We investigated whether cyclin D1 could directly interact with
P/CAF in cultured cells. To determine whether cyclin D1 formed a
complex with P/CAF, 293T cells were transfected with cyclin D1, P/CAF,
and either with or without the AR. IP-Western blotting was then
performed to assess complexes binding to cyclin D1 (Fig. 6
). The cyclin D1 IP was immunoreactive
for cyclin D1, AR, and P/CAF (Fig. 6A
lanes 1 and 5). The supernatant
(S) was free of cyclin D1 and contained approximately 50% of the
remaining P/CAF (Fig. 6A
, lane 2). IP with a control IgG contained
neither cyclin D1 nor P/CAF (Fig. 6A
, lane 3). AR Western blotting
demonstrated AR in the cyclin D1 IP and in the supernatant (Fig. 6A
, lanes 1 vs. 2). Approximately 35% of the total AR was bound
to cyclin D1 and approximately 50% of the cellular P/CAF was bound to
cyclin D1.

View larger version (33K):
[in this window]
[in a new window]
|
Figure 6. Cyclin D1 Binds P/CAF and AR in Cultured Cells
Expression vectors encoding cyclin D1 and P/CAF with or without
the AR were transfected into 293T cells. Cells were either untreated
(A) or treated with DHT (10-7 M) for 24 h
(B). Cellular extracts were assessed by cyclin D1 IP with comparison to
equal amounts of control IgG. The precipitate (IP) and the supernatant
(S) were subjected to Western blotting with the indicated antibodies
for AR, P/CAF, or cyclin D1. In panel C, murine liver extracts were
subjected to direct Western blotting (lane 1) or IP with the AR
antibody and subsequent Western blotting of the IP (lane 2). The AR-IP
contains AR, P/CAF, and cyclin D1 by Western blot.
|
|
We examined the possibility that DHT may change the relative
distribution of AR as either bound or unbound to cyclin D1. Cells were
transfected with expression plasmids for cyclin D1, AR, and P/CAF and
treated with DHT for 24 h. Cyclin D1-IP Western blot analysis
showed that the cyclin D1 IP was saturating (Fig, 6B, compare cyclin D1
Western blot, lanes 1 vs. 2). The relative proportion of AR
not bound to cyclin D1 was increased by DHT, and the proportion of
P/CAF associated with cyclin D1 was reduced. The relative abundance of
P/CAF in the supernatant compared with the cyclin D1-bound fraction was
approximately 5:1 assessed by Western blotting. Cyclin D1-IP with
subsequent Western blotting was also performed on cells transfected
with cyclin D1 and P/CAF. In this circumstance the addition of DHT did
not increase the proportion of P/CAF unbound to cyclin D1 (Fig. 6B
lanes 5 vs. 6). This finding suggests the decrease in P/CAF
binding to cyclin D1 upon the addition of DHT is likely due to the
presence of the AR.
To determine whether the AR binds to cyclin D1 or P/CAF in
vivo, IP-Western blotting was performed using extracts from murine
liver with comparison made to direct Western blotting of the
hepatocellular extracts (Fig. 6C
, lane 2 vs. 1). The AR
antibody immunoprecipitated the AR (Fig. 6C
, lane 2) and no
immunoreactive AR band was observed in control IgG (not shown). The AR
IP was also immunoreactive for cyclin D1 and for P/CAF. These studies
demonstrate that the cyclin D1-AR interaction observed in cultured
cells is also observed in tissues.
As these studies showed P/CAF can be immunoprecipitated in association
with cyclin D1, it remained to be determined whether cyclin D1 could
interact directly with specific domains of P/CAF. Several
transcriptional activators, viral proteins, and coactivators have been
shown to interact directly with P/CAF. GST pull-down experiments were
therefore conducted with affinity-purified P/CAF and GST cyclin D1 or
GST alone as a control (Fig. 7
). The
amount of P/CAF protein was confirmed by Western blotting using the
Flag epitope (Fig. 7
, upper panel). Incubation of
affinity-purified P/CAF with GST alone showed no interaction (Fig. 7
, middle panel). Incubation of affinity-purified P/CAF with
GST-cyclin D1 showed strong binding (>20% of the input). The P/CAF
internal deletion mutants of the HAT (
511656), Ada2 homology
region (
655701), and bromo domain (
729832) were defective in
binding to cyclin D1. In addition, the internal deletion mutant
5122 was defective in binding to cyclin D1. The domains of P/CAF
required for binding to cyclin D1 resemble the domains required for
binding to the AR (35), raising the possibility that cyclin D1 may
inhibit AR function by binding to the same sites on P/CAF.

View larger version (31K):
[in this window]
[in a new window]
|
Figure 7. P/CAF Binds to Cyclin D1 and the AR through
Overlapping Domains
Affinity-purified Flag-P/CAF proteins (shown schematically) were
incubated with equal amounts of full-length GST cyclin D1. Western
blotting of the P/CAF mutant proteins using the Flag antibody
(upper panel) confirmed that equal amounts of wild-type
and mutant P/CAF proteins were incubated in the pull-down experiment.
GST alone did not pull down P/CAF (middle panel). Cyclin
D1-bound P/CAF protein was confirmed by Western blotting (lower
panel). Domains of interaction between P/CAF and cyclin D1
identified by pull down are scored as + or -. The domains of P/CAF
that bind the AR are also shown [Data reproduced from Ref.
35].
|
|
Cyclin D1 Inhibits P/CAF Binding to the AR in
Vitro
As cyclin D1 bound to similar domains of P/CAF, and P/CAF
enhanced AR activity, we considered the possibility that cyclin D1 may
inhibit AR activity by competing with the AR for P/CAF binding. To
examine this possibility, we assessed the effect of cyclin D1 on the
association between P/CAF and AR in vitro. Purified
Flag-tagged P/CAF produced in baculovirus was incubated with
GST-AR505-676 and IP
performed with the M2 Flag antibody (Fig. 8
). Western blotting of the P/CAF IP
using a GST antibody demonstrated the presence of the
GST-AR505-676 fusion
protein (Fig. 8
, lower panel) indicating P/CAF and AR are
capable of interacting in a pull-down assay. The preaddition of excess
GST-cyclin D1 to the mix of Flag-tagged P/CAF and
GST-AR505-676 fusion
protein abolished the presence of immunodetectable
GST-AR505-676 in the P/CAF
IP (Fig. 8
, lane 4, lower panel). The preaddition of equal
molar amounts of GST protein did not interfere with the binding of
P/CAF to GST-AR (Fig. 8
lane 2, lower panel). GST-cyclin D1
was observed in the supernatant by Western blotting in conjunction with
AR505-676 (Fig. 8
, lane
3). These studies suggest that cyclin D1 has the
capacity to inhibit the association between P/CAF and the AR in
vitro.

View larger version (30K):
[in this window]
[in a new window]
|
Figure 8. Cyclin D1 Inhibits AR Binding to P/CAF in
Vitro
The in vitro association between AR and P/CAF was
determined in pull-down studies in the absence of ligand. Flag-tagged
P/CAF was incubated with GST-AR, and IP was performed with saturating
amounts of the M2 anti-Flag antibody. The IP and supernatant (S) were
subjected to Western blotting with antibodies to the AR and GST for
cyclin D1. The presence of GST-AR in the P/CAF (M2) IP was confirmed
through Western blotting for the AR. The addition of GST-cyclin D1 in
excess (lane 4) abolished GST-AR binding to P/CAF as evidenced by the
loss of AR immunoreactivity in the M2 IP. The presence of cyclin D1 in
the supernatant with the AR (lane 3) is consistent with the binding of
AR to cyclin D1 (Fig. 3B ).
|
|
 |
DISCUSSION
|
---|
In the current studies, cyclin D1 repressed ligand-dependent AR
transactivation. Cyclin D1-mediated repression of liganded AR activity
was observed in pRB-deficient cells, and mutation of the pRB-binding
domain of cyclin D1 did not abrogate repression. These findings
suggest that the ability of cyclin D1 to inhibit liganded AR activity
is distinct from its pRB phosphorylation function. Cyclin D1
regulation of liganded AR activity required the carboxyl-terminal
acid-rich region of cyclin D1 and a carboxyl- terminal LXXXLL motif.
The domains of cyclin D1 that were required for repression of liganded
AR activity were also required for binding to the AR. These findings
suggest that either binding of cyclin D1 to the AR is required to form
a repressor complex or that the domain of cyclin D1 that binds to the
AR may compete with the AR for a common limiting factor. The current
studies are fundamentally different from the previously described
interaction between cyclin D1 and the estrogen receptor
(ER
). In
contrast with the current studies in which cyclin D1 selectively
inhibited liganded AR activity, it is the activity of the unliganded
ER
that is induced by cyclin D1 (31, 36). Although cyclin D1 binds
to ER
in cultured cells, it is not known which residues of either
ER
or of cyclin D1 are required for direct interaction (37). The
carboxyl-terminal LXXXLL motif of cyclin D1 plays a role in cyclin
D1-mediated induction of basal ER
activity through recruiting SRC-1
(36). Although the ER
is capable of binding to cyclin D1 (31, 36)
and P/CAF (38), the domains of P/CAF binding to the ER
are distinct
from the regions binding to the AR (data not shown). Thus, the domains
of P/CAF bound by the nuclear receptor may determine functional
interactions with cyclin D1.
The association between cyclin D1 and the AR demonstrated by IP-Western
blotting of cultured cells and using in vitro analysis
suggests the basic region of the AR interacts with the carboxy-terminal
region of cyclin D1. The domains of cyclin D1 required for binding to
the AR correlated well with the regions required for transcriptional
repression of the ligand-bound AR. Cyclin D2 and D3 neither repressed
ligand-induced AR activity nor bound to this region of the AR in GST
pull-down experiments. This finding suggests that the structural
divergence among the D type cyclins in this region may abrogate
critical determinants for AR binding. The
C274 mutant was 50%
defective in repression of DHT-induced MMTV-LUC activity and bound AR
with 35% of wild-type binding affinity on GST pull-down analyses (Fig. 2C
). The region of cyclin D1 from 267 to 274 was absolutely required
for both binding to the AR and for repression of liganded AR activity.
Alignment of cyclin D1 and structural comparison with cyclin A suggests
the acid-rich region (267 PKAAEEEE 271) and leucine-containing motif
(LLXXXL), required for AR binding, align at the C terminus of helix 5.
The structure of cyclins A and H deduced through crystallization
reveals a core of two repeats containing five
-helical bundles that
form the cyclin fold (39). The likely amphipathic
-helical
structure of cyclin D1 within the AR interaction domain may serve
as an interaction domain with other proteins. The region of the AR
involved in direct binding to cyclin D1 (residues 633668) contains
predominantly basic residues, suggesting an ionic basis for binding to
cyclin D1.
In the current studies deletion of the p300 CH3 domain abolished relief
of cyclin D1-mediated AR transrepression. Both p300 and P/CAF have
intrinsic HAT function. Deletion of the P/CAF HAT domain, but not the
p300 HAT domain, abolished its ability to relieve cyclin D1-mediated AR
repression. As the p300 CH3 region is capable of binding P/CAF, it is
likely that the p300 CH3 mutant is defective through failed recruitment
of P/CAF. The finding that P/CAF HAT activity, but not p300 HAT
activity, was required for relief of cyclin D1-mediated AR
transrepression is consistent with recent observations in which the
acetyltransferase activities and substrate specificities of p300 and
P/CAF were shown to be distinguishable (40). These findings are also
consistent with previous observations that the functional activities of
p300 and P/CAF are restricted to specific activators or promoters (17, 41). In transfection assays, ligand-induced AR activity was inhibited
by cyclin D1 and enhanced by P/CAF. The mutual antagonism between
cyclin D1 and the AR may be due to competition for binding to a common
intermediary protein or a limiting cofactor such as P/CAF. In support
of a model in which cyclin D1 and AR may compete for a common
intermediary protein are the in vitro findings that cyclin
D1 and the AR bound to similar regions of P/CAF (Fig. 7
) and that the
preaddition of GST cyclin D1 fusion protein inhibited the binding of
P/CAF to the AR (Fig. 8
). Support for the biological relevance of the
association between cyclin D1 and the AR include our findings that the
AR was associated with cyclin D1 and P/CAF in vivo, and in
transfected cells using IP-Western blot analysis (Fig. 6
). Furthermore,
the associations between cyclin D1 and the AR appear to be hormone
regulated. Thus, in cultured cells, the amount of P/CAF associated with
cyclin D1 was reduced by the presence of liganded AR. Together, these
studies suggest that cyclin D1 inhibition of liganded AR activity may
be due to mutually exclusive binding of cyclin D1 and AR for P/CAF. As
P/CAF forms a multiprotein complex, it is likely that additional
components regulating this interaction in vivo remain to be
determined. As the domain of P/CAF that binds to cyclin D1 overlaps the
Twist binding domain (42), it will be of interest to
determine whether the differentiation function of Twist or
other basic helix-loop-helix proteins are also regulated by cyclin
D1.
The current studies, however, provide evidence that cyclin D1 can
selectively and specifically inhibit liganded AR activity. Cyclin D1
can inhibit differentiation and either promote or inhibit cellular
proliferation in a cell type-specific manner (reviewed in Ref. (43).
The AR also has both differentiation and proliferation functions. For
example, the DHT-liganded AR plays an important role in the induction
of male secondary sexual characteristics (3). Thus, AR gene mutations
described in complete androgen insensitivity syndrome causes XY
genotypic males to develop as phenotypic females due to defective AR
function (44). In cultured prostatic cells, DHT can induce
differentiation, as evidenced by the cell cycle arrest and increased
expression of enzymatic differentiation markers (45) or proliferation
in cell lines with mutant AR (46). Because of the functional redundancy
between components of the cell cycle-regulatory apparatus, it may be
difficult to dissect the independent contribution of cyclin D1 to
liganded AR activity in vivo. The AR is located in a broad
array of tissues and contributes to diverse signal transduction
pathways in breast, brain, and prostate, and the role of cyclin D1 in
regulating signal transduction in these tissues remains to be
determined.
Cyclin D1 binding to P/CAF in vitro required the HAT
domain of P/CAF. Mutational analysis of the Gcn5p HAT domain identified
four subdomains with catalytic activity mediated through the
carboxyl-terminal subdomains (47). Mutation within subdomain IV of
Gcn5p abolished HAT activity in vitro (47). In the current
studies an expression plasmid encoding a deletion within the HAT domain
abolished rescue of cyclin D1 repression of liganded AR activity. The
carboxyl-terminal bromodomain of P/CAF, which forms a four-helix bundle
that interacts specifically with acetylated lysine (48), remains intact
in this mutant and may therefore reduce AR activity by competing with
endogenous P/CAF. Although speculative at this time, our studies
predict that the binding of cyclin D1 to the HAT domain of P/CAF may
regulate other functions of P/CAF. P/CAF HAT activity contributes to
regulation of transcription, inhibition of cell cycle progression, and
the induction of differentiation (18, 41). The cyclin D1
gene product, in contrast, can inhibit differentiation and promote cell
cycle progression in several cell types. P/CAF is associated with at
least 20 polypeptides in cultured cells including the TBP-associated
factors (TAFs), which are subunits of transcription factor IID
(TFIID), and other TAFs (49). The association of P/CAF with these
polypeptides and the direct HAT activity conveyed by P/CAF may both
contribute to the regulation of AR function. P/CAF has the capacity to
augment gene expression both by acetylating core histones and also by
directly acetylating a subset of transcription factors including p53
(50) and the AR (35) reviewed previously (41). The contribution of
cyclin D1 to other functions of P/CAF remains to be explored.
 |
MATERIALS AND METHODS
|
---|
Plasmids, Transfections, and Reporter Assays
The expression vectors pCMV-cyclin D1, CMV-cyclin D1-KE, and
CMV-cyclin D1 GH (51), pCMVHA p300, p300
17371809,
14191721
(15), pCMVHA
bromop300, which deletes residues 1,0321,138 of p300,
rP/CAF, P/CAF
609624 (52), were previously described. The
reporter plasmids c-fos LUC, c-Jun LUC, JunB LUC,
SRELUC, E2F LUC, cyclin D1 LUC, cyclin E LUC,
p21Cip1/WAF1 LUC, CMV LUC, and RSV LUC were
previously described (23, 53, 54, 55). The human cyclin D1 mutants were
derived by PCR-directed amplification using sequence-specific primers
and cloned into pRc/CMV, and the integrity of all constructs was
confirmed by sequence analysis. The AR expression vectors, ARWt,
AR
8093, AR96483, and AR 1707 (56), and fusion proteins,
GST-AR/676844, GST-AR/676919, GST-AR/505919, GST-AR/505676,
GST-AR/505559, GST-AR/552635, and GST-AR/633668 (57), the
reporter MMTV-LUC (from Dr. R. Evans), and the Flag-tagged P/CAF
mutants (42) were previously described. GST-cyclin D2 and GST-cyclin D3
were gifts from Dr. M. Pagano.
Cell culture, DNA transfection, and luciferase assays were performed as
previously described (53, 54). A CMV-Renilla luciferase plasmid,
pRL-CMV (Promega Corp., Madison, WI), was included to
control for transfection efficiency as indicated. Renilla luciferase
activity was assayed according to the manufacturers instructions for
the Dual-Luciferase Reporter Assay System. The prostate cancer cell
lines PC3 and DU145 (ATCC, Manassas, VA) and the 293T cell
line were cultured in DMEM with 10% charcoal-stripped FCS, 1%
penicillin, and 1% streptomycin. Cells were transfected by calcium
phosphate precipitation or lipofection using lipofectamine PLUS
(Life Technologies, Inc., Gaithersburg, MD), the medium
was changed after 6 h or 3 h, respectively, and luciferase
activity was determined after 48 h. At least two different plasmid
preparations of each construct were used. In cotransfection
experiments, a dose-response was determined in each experiment with 300
ng and 600 ng of expression vector and the promoter reporter plasmids
(2.4 µg). Luciferase activity was normalized for transfection using
the renilla luciferase as internal control as previously described.
Luciferase assays were performed at room temperature using an Autolumat
LB 953 (EG&G Berthold) as previously described (53). The -fold
effect was determined for 300600 ng of expression vector with
comparison made to the effect of the empty expression vector cassette,
and statistical analyses were performed using the Mann-Whitney
U test.
Western Blots
The antibodies used in Western blot analysis were a monoclonal
cyclin D1 antibody DCS-6 (NeoMarkers Lab Vision Corp., Fremont, CA), a
rabbit anti-P/CAF antibody (18), an
-guanine nucleotide dissociation
inhibitor (GDI) (58) (a gift from Dr. Perry Bickel, Washington
University St. Louis, MO, used as internal control for protein
abundance), anti-M2 Flag antibody (Sigma, St. Louis, MO),
and antibodies from Santa Cruz Biotechnology, Inc., (Santa
Cruz, CA): cyclin D1 antibody (HD11), GST (B-14), and AR (N-20). For
detection of cyclin D1, the membrane was incubated with antimouse
cyclin D1 antibody DCS-6 (NeoMarkers Lab Vision Corp.), washed with
0.05% TPBS three times, and then incubated with horseradish
peroxidase-conjugated secondary antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) and washed again. An
antirabbit horseradish peroxidase-conjugated secondary antibody was
used for AR (1:3,000), and an antimouse horseradish
peroxidase-conjugated secondary antibody was used for the Flag epitope
(1:2,000). Proteins were visualized by the enhanced chemiluminescence
system (Amersham Pharmacia Biotech, Arlington Heights,
IL). The abundance of immunoreactive protein was quantified by
phosphoimaging using a computing densitometer (Image Quant version
1.11, Molecular Dynamics, Inc., Sunnyvale, CA).
Protein Interaction Assays in Vitro and in Cultured
Cells and in Vivo
In vitro
[35S]methionine-labeled proteins were prepared
by coupled transcription-translation with a TNT coupled reticulocyte
lysate kit (Promega Corp., Madison, WI), using 1.0 µg of
plasmid DNA in a total of 50 µl. Flag-tagged P/CAF proteins were
expressed in Sf9 cells by infecting with recombinant baculovirus and
were purified as described (15). GST fusion proteins were prepared from
Escherichia coli cells as described previously (42). GST
fusion proteins were induced for 4 h at 30 C with 0.1
M
isopropyl-ß-D-thiogalactopyranoside, and crude
lysates were prepared at 4 C. Cell pellets were spun down and
resuspended in 15 ml PBS containing 2 mM
dithiothreitol (DTT), 1 mM
phenylmethylsulfonylfluoride (PMSF), 1 µg/ml pepstatin, 1 µg/ml
leupeptin, and 1 µg/ml aprotinin. Lysozyme (2 mg/sample) was added
and incubation performed on ice for 10 min. Samples were sonicated
using 20-sec pulses until lysed. One milliliter of 15% Triton X-100 in
PBS was added, and the samples were then centrifuged at 40,000 rpm for
15 min at 4 C. The supernatant was added to 500 µl of glutathione
sepharose beads (Amersham Pharmacia Biotech), and the
mixture was rotated at 4 C overnight. The supernatant was discarded and
the pellet washed three times in PBS containing 100
mM DTT and 1% Tween 20, and three times in PBS
containing 50 mM Tris-HCl and 5
mM DTT (pH 8.0). The pellet was resuspended in
400 µl of this buffer and 50 µl of glutathione (100
mM in Tris HCl, pH 8.0) were added. Elution of
proteins was performed for 1 h, and beads were separated by
centrifugation. Glutathione was removed by dialysis at 4 C in 20
mM Tris, 25 mM NaCl, and 2
mM EDTA.
In vitro protein-protein interactions were performed
as described (31). The in vitro translated protein (15 µl
of cyclin D1) was added to 5 µg of GST or equal amounts of GST-AR, in
225 µl of binding buffer (50 mM Tris-HCl, 120
mM NaCl, 1 mM DTT, 0.5%
NP-40, 1 mM EDTA, 2 µg/ml leupeptin, 2 µg/ml
aprotinin, 1 mM PMSF, 2 µg/ml pepstatin) and
rotated for 2 h at 4 C. Fifty microliters of glutathione-sepharose
bead slurry were added, and the mixture was rotated for a further 30
min at 4 C. Beads were washed five times with 1 ml of binding buffer
and 30 µl of binding buffer were added after the final wash.
Baculovirus- expressed Flag-tagged P/CAF (1 µg) was used in
pull-down experiments as previously described (35). In competition
experiments baculovirus P/CAF (1 µg) was incubated with
GST-AR505-676 (1 µg),
and IP was performed with the M2 (Flag) antibody. Competition was
performed through preincubation with GST-cyclin D1 (1 µg) or GST (1
µg) alone.
IP Western blot analysis was performed with murine hepatic tissue (as
previously described) (59) or 293T cells. 293T cells transfected with
pSV-AR, pCMV-cyclin D1, pCI-P/CAF, or expression vector control were
treated for 36 h with 10-7 M
DHT or vehicle as control. Cells were rinsed with PBS, harvested by
scraping, pelleted, and lysed in buffer (50 mM HEPES, pH
7.2, 150 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 1 mM DTT, 0.1% Tween 20, 0.1 mM PMSF,
2.5 µg/ml leupeptin, 0.1 mM sodium orthovanadate
(Sigma). Extracts were cleared by centrifugation and
further precleared by rocking at 4 C with washed protein A Sepharose
(Roche Molecular Biochemicals, Indianapolis, IN). Five
hundred micrograms of precleared extract were immunoprecipitated with 1
µg of cyclin D1 antibody (DCS-11, NeoMarkers Lab Vision Corp.) or AR
antibody (N-20, Santa Cruz Biotechnology, Inc., Santa
Cruz, CA) or equivalent amounts of appropriate control IgG (Santa Cruz Biotechnology, Inc.) and 50 µl of protein A sepharose for
812 h at 4 C. Beads were washed five times with lysis buffer and
boiled in SDS sample buffer, and released proteins were resolved by
10% SDS-PAGE. The gel was transferred to nitrocellulose and Western
blotting was performed.
 |
ACKNOWLEDGMENTS
|
---|
We thank Drs. M. Avantagiatti, D. Baltimore, S. Bhattacharya, R.
Echner, P. Hinds, D. Livingston, A. Minden, and Y. Nakatani for
reagents and helpful discussion.
 |
FOOTNOTES
|
---|
Address requests for reprints to: Richard G. Pestell, The Albert Einstein Cancer Center, Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Chanin 302, 1300 Morris Park Ave, Bronx, New York 10461. E-mail pestell{at}aecom.yu.edu
This work was supported by an award from the Pfeiffer Foundation,
RO1CA70897 and RO1CA75503 (to R.G.P.), NIH Grants CA-70297 (Z.J.S.),
and American Cancer Society Grant RPG98213 (Z.J.S.). Work conducted at
the Albert Einstein College of Medicine was supported by Cancer Center
Core NIH Grant 5-P30-CA1333026.
1 These authors contributed equally to the manuscript. 
Received for publication September 11, 2000.
Revision received January 9, 2001.
Accepted for publication January 30, 2001.
 |
REFERENCES
|
---|
-
Tsai MJ, OMalley BW 1994 Molecular mechanisms of action
of steroid/thyroid receptor superfamily members. Annu Rev Biochem 63:451486[CrossRef][Medline]
-
Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS, Tung
L 1996 Nuclear receptor coactivators and corepressors. Mol Endocrinol 10:11671177[Abstract]
-
Quigley CA, De Bellis A, Marschke KB, El-Wady MK, Wilson EM,
French FS 1995 Androgen receptor defects: historical, clinical, and
molecular perspectives. Endocr Rev 16:271321[Medline]
-
Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE,
Ogata GK, Keer HN, Balk SP 1995 Mutation of the androgen-receptor gene
in metastatic androgen-independent prostate cancer. N Engl J
Med 332:13931398[Abstract/Free Full Text]
-
Beato M, Sanchez-Pacheco A 1996 Interaction of steroid
hormone receptors with the transcription initiation complex. Endocr Rev 17:587609[Medline]
-
Sadovsky Y, Webb P, Lopez G, Baxter JD, Fitzpatrick PM,
Gizang-Ginsberg E, Cavailles V, Parker MG, Kushner PJ 1995 Transcriptional activators differ in their responses to overexpression
of TATA-box-binding protein. Mol Cell Biol 15:15541563[Abstract]
-
Pugh BF, Tjian R 1990 Mechanism of transcriptional activation
by Sp1: evidence for coactivators. Cell 61:11871197[Medline]
-
Janknecht T, Hunter T 1996 A growing coactivator network.
Nature 383:2223[CrossRef][Medline]
-
McKenna J, Lanz RB, OMalley BW 1999 Nuclear receptor
co-regulators: cellular and molecular biology. Endocr Rev 20:321344[Abstract/Free Full Text]
-
Lanz RB, McKenna NJ, Onate SA, Albrecht U, Wong J, Tsai SY,
Tsai MJ, OMalley BW 1999 A steroid receptor coactivator, SRA,
functions as an RNA and is present in an SRC-1 complex. Cell 97:1727[Medline]
-
Mak HY, Hoare S, Henttu PMA, Parker MG 1999 Molecular
determinants of the estrogen receptor-coactivator interface. Mol Cell
Biol 19:38953903[Abstract/Free Full Text]
-
Martinez-Balbas MA, Bannister AJ, Martin K, Haus-Seuffert P,
Meisterernst M, Kouzarides T 1998 The acetyltransferase activity of CBP
stimulates transcription. EMBO J 17:28862893[Abstract/Free Full Text]
-
Nakajima T, Uchida C, Anderson SF, Lee C-G, Hurwitz J, Parvin
JD, Montminy M 1997 RNA helicase A mediates association of CBP with RNA
polymerase II. Cell 90:11071112[Medline]
-
Bannister AJ, Kouzarides T 1996 The CBP coactivator is a
histone acetyltransferase. Nature 384:641643[CrossRef][Medline]
-
Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y 1996 The transcriptional coactivators p300 and CBP are histone
acetyltransferases. Cell 87:953959[Medline]
-
Wolffe AP 1997 Histone deacetylase: a regulator of
transcription. Science 272:371372[CrossRef][Medline]
-
Struhl K 1998 Histone acetylation and transcriptional
regulatory mechanisms. Genes Dev 12:599606[Free Full Text]
-
Yang X-J, Ogryzko VV, Nishikawa J-i, Howard BH 1996 A
p300/CBP-associated factor that competes with the adenoviral
oncoprotein E1A. Nature 382:319324[CrossRef][Medline]
-
Puri PL, Avantaggiati ML, Balsano C, Sang N, Graessmann A,
Giordano A, Levrero M 1997 p300 is required for MyoD-dependent
cell-cycle arrest and muscle-specific gene transcription. EMBO J 16:369383[Abstract/Free Full Text]
-
Weinberg RA 1995 The retinoblastoma protein and cell cycle
control. Cell 81:323330[Medline]
-
Sherr CJ, Roberts JM 1995 Inhibitors of mammalian G1
cyclin-dependent kinases. Genes Dev 9:11491163[CrossRef][Medline]
-
Lovec H, Grzeschiczek A, Kowalski MB, Moroy T 1994 Cyclin
D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma
in transgenic mice. EMBO J 13:34873495[Abstract]
-
Albanese C, Johnson J, Watanabe G, Eklund N, Vu D, Arnold A,
Pestell RG 1995 Transforming p21ras mutants and
c-Ets-2 activate the cyclin D1 promoter through distinguishable
regions. J Biol Chem 270:2358923597[Abstract/Free Full Text]
-
Westwick JK, Lee RJ, Lambert QT, Symons M, Pestell RG, Der CJ,
Whitehead IP 1998 Transforming potential of Dbl family proteins
correlates with transcription from the cyclin D1 promoter but not with
activation of Jun NH2-terminal kinase, p38/Mpk2,
serum response factor, or c-Jun. J Biol Chem 273:1673916747[Abstract/Free Full Text]
-
Westwick JK, Lambert QT, Clark GJ, Symons M, Van Aelst L,
Pestell RG, Der CJ 1997 Rac regulation of transformation, gene
expression and actin organisation by multiple, PAK-independent
pathways. Mol Cell Biol 17:13241335[Abstract]
-
Lee RJ, Albanese C, Stenger RJ, Watanabe G, Inghirami G,
Haines GKI, Webster M, Muller WJ, Brugge JS, Davis RJ, Pestell
RG 1999 pp60v-src induction of cyclin D1
requires collaborative interactions between the extracellular
signal-regulated kinase, p38, and Jun kinase pathways: a role for cAMP
response element-binding protein and activating transcription factor-2
in pp60v-src signaling in breast cancer cells.
J Biol Chem 274:73417350[Abstract/Free Full Text]
-
Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG,
Albanese C, Darnell JE 1999 Stat3 as an oncogene. Cell 98:295303[Medline]
-
Shtutman M, Zhurinsky J, Simcha I, Albanese C, DAmico M,
Pestell R, Ben-Zeev A 1999 The cyclin D1 gene is a target of the
ß-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 96:55225527[Abstract/Free Full Text]
-
Rao SS, Kohtz DS 1995 Positive and negative regulation of
D-type cyclin expression in skeletal myoblasts by basic fibroblast
growth factor and transforming growth factor ß. A role for cyclin D1
in control of myoblast differentiation. J Biol Chem 270:40934100[Abstract/Free Full Text]
-
Skapek S, Rhee J, Kim PS, Novitch B, Lassar A 1996 Cyclin
mediated inhibition of muscle gene expression via a mechanism that is
independent of pRB phosphorylation. Mol Cell Biol 16:70437053[Abstract]
-
Neuman E, Ladha MH, Lin N, Upton TM, Miller SJ, DiRenzo J,
Pestell RG, Hinds PW, Dowdy SF, Brown M, Ewen ME 1997 Cyclin D1
stimulation of estrogen receptor transcriptional activity independent
of cdk4. Mol Cell Biol 17:53385347[Abstract]
-
Zwijsen RML, Wientjens E, Klompmaker R, van der Sman J,
Bernards R, Michalides RJAM 1997 CDK-independent activation of estrogen
receptor by cyclin D1. Cell 88:405415[Medline]
-
Zwijsen RML, Klompmaker R, Wientjens EBHGM, Kristel PMP, van
der Burg B, Michalides RJAM 1996 Cyclin D1 triggers autonomous growth
of breast cancer cells by governing cell cycle exit. Mol Cell Biol 16:25542560[Abstract]
-
Reid JL, Bannister AJ, Zegerman P, Martinez-Balbas MA,
Kouzarides T 1998 E1A directly binds and regulates the P/CAF
acetyltransferase. EMBO J 17:44694477[Abstract/Free Full Text]
-
Fu M, Wang C, Reutens AT, Angelletti R, Siconolfi-Baez L,
Ogryzko V, Avantaggiati ML, Pestell RG 2000 p300 and P/CAF acetylate
the androgen receptor at sites governing hormone-dependent
transactivation. J Biol Chem 275:2085320860[Abstract/Free Full Text]
-
Zwijsen RML, Buckle RS, Hijmans EM, Loomans CJM, Bernards R 1998 Ligand-independent recruitment of steroid receptor coactivators to
estrogen receptor by cyclin D1. Genes Dev 12:34883498[Abstract/Free Full Text]
-
Lamb J, Ladha MH, McMahon C, Sutherland RL, Ewen ME 2000 Regulation of the functional interaction between cyclin D1 and the
estrogen receptor. Mol Cell Biol 20:86678675[Abstract/Free Full Text]
-
McMahon C, Suthiphongchai T, DiRenzo J, Ewen ME 1999 P/CAF
associates with cyclin D1 and potentiates its activation of the
estrogen receptor. Proc Natl Acad Sci USA 96:53825387[Abstract/Free Full Text]
-
Andersen G, Busso D, Poterszman A, Hwang JR, Wurtz JM, Ripp R,
Thierry JC, Egly JM, Moras D 1997 The structure of cyclin H: common
mode of kinase activation and specific features. EMBO J 16:958967[Abstract/Free Full Text]
-
Schiltz RL, Mizzen CA, Vassilev A, Cook RG, Allis CD, Nakatani
Y 1999 Overlapping but distinct patterns of histone acetylation by the
human coactivators p300 and PCAF within nucleosomal substrates. J
Biol Chem 274:11891192[Abstract/Free Full Text]
-
Kouzarides T 1999 Histone acetylase and deacetylases in cell
proliferation. Curr Opin Genet Dev 9:4048[CrossRef][Medline]
-
Hamamori Y, Sartorelli V, Ogryzko V, Puri PL, Wu HY, Wang JY,
Nakatani Y, Kedes L 1999 Regulation of histone acetyltransferases p300
and PCAF by the bHLH protein twist and adenoviral oncoprotein E1A. Cell 96:405413[Medline]
-
Pestell RG, Albanese C, Reutens AT, Segall JE, Lee RJ, Arnold
A 1999 The cyclins and cyclin-dependent kinase inhibitors in hormonal
regulation of proliferation and differentiation. Endocr Rev 20:501534[Abstract/Free Full Text]
-
Brown TR, Lubahn DB, Wilson EM, Joseph DR, French FS, Migeon
CJ 1988 Deletion of the steroid-binding domain of the human androgen
receptor gene in one family with complete androgen insensitivity
syndrome: evidence for further genetic heterogeneity in this syndrome.
Proc Natl Acad Sci USA 85:81518155[Abstract]
-
Lee C, Sutkowski DM, Sensibar JA, Zelner D, Kim I, Amsel I,
Shaw N, Prins GS, Kozlowski JM 1995 Regulation of proliferation and
production of prostate-specific antigen in androgen-sensitive prostatic
cancer cells, LNCaP, by dihydrotestosterone. Endocrinology 136:796803[Abstract]
-
Chen Y, Martinez LA, LaCava M, Coghlan L, Conti CJ 1998 Increased cell growth and tumorigenicity in human prostate LNCaP cells
by overexpression to cyclin D1. Oncogene 16:19131920[CrossRef][Medline]
-
Kuo M-H, Zhou J, Jambeck P, Churchill MEA, Allis CD 1998 Histone acetyltransferase activity of yeast Gcn5p is required for the
activation of target genes in vivo. Genes Dev 12:627639[Abstract/Free Full Text]
-
Dhalluin C, Carlson J, Zeng L, He C, Aggarwal A, Zhou M 1999 Structure and ligand of a histone acetyltransferase bromodomain. Nature 399:491496[CrossRef][Medline]
-
Ogryzko VV, Kotani T, Zhang X, Schlitz RL, Howard T, Yang XJ,
Howard BH, Qin J, Nakatani Y 1998 Histone-like TAFs within the PCAF
histone acetylase complex. Cell 94:3544[Medline]
-
Gu W, Roeder RG 1997 Activation of p53 sequence-specific DNA
binding by acetylation of the p53 C-terminal domain. Cell 90:595606[Medline]
-
Hinds PW, Dowdy SF, Eaton EN, Arnold A, Weinberg RA 1994 Function of a human cyclin gene as an oncogene. Proc Natl Acad Sci USA 91:709713[Abstract]
-
Blanco JCG, Minucci S, Lu J, Yang X-J, Walker KK, Chen H,
Evans RM, Nakatani Y, Ozato K 1998 The histone acetylase PCAF is a
nuclear receptor coactivator. Genes Dev 12:16381651[Abstract/Free Full Text]
-
Watanabe G, Albanese C, Lee RJ, Reutens A, Vairo G, Henglein
B, Pestell RG 1998 Inhibition of cyclin D1 kinase activity is
associated with E2F-mediated inhibition of cyclin D1 promoter activity
through E2F and Sp1. Mol Cell Biol 18:32123222[Abstract/Free Full Text]
-
Fan S, Wang. J-A, Yuan R, Ma Y, Meng Q, Erdos MR, Pestell RG,
Yuan F, Auborn KJ, Goldberg ID, Rosen E 1999 BRCA1 inhibition of
estrogen receptor signaling in transfected cells. Science 284:13541356[Abstract/Free Full Text]
-
Clarke N, Arenzana N, Hai T, Minden A, Prywes R 1998
Epidermal growth factor induction of the c-jun promoter by a Rac
pathway. Mol Cell Biol 18:10651073[Abstract/Free Full Text]
-
Gao T, Marcelli M, McPhaul MJ 1996 Transcriptional activation
and transient expression of the human androgen receptor. J Steroid
Biochem Mol Biol 59:920[CrossRef][Medline]
-
Sun Z, Pan J, Balk SP 1997 Androgen receptor-associated
protein complex binds upstream of the androgen-responsive elements in
the promoter of human prostate-specific antigen and kallikrein genes.
Nucleic Acids Res 25:33183325[Abstract/Free Full Text]
-
DAmico M, Hulit J, Amanatullah D, Zafonte BT, Albanese C,
Maofu Fu M, Ikui A, Donehower LA, Shtutman M, Ben-Zeev A, Dedhar S,
Takemaru K-I, Moon RT, Pestell RG 2000 The integrin-linked
kinase regulates the cyclin D1 gene through glycogen synthase kinase 3b
and CREB-dependent pathways. J Biol Chem 275:3264932657[Abstract/Free Full Text]
-
Bouzahzah B, Fu M, Iaavarone A, Factor VM, Thorgeirsson SS,
Pestell RG 2000 Transforming growth factor ß1 recruits histone
deacetylase 1 to a p130 repressor complex in trangenic mice in
vivo. Cancer Res 60:45314537[Abstract/Free Full Text]